Guggenheim Capital’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-13,849
| Closed | -$207K | – | 2065 |
|
|
2022
Q4 | $207K | Buy |
+13,849
| New | +$192K | ﹤0.01% | 1801 |
|
|
2018
Q2 | – | Sell |
-2,581
| Closed | -$75K | – | 2732 |
|
|
2018
Q1 | $75K | Buy |
2,581
+287
| +13% | +$8.4K | ﹤0.01% | 2678 |
|
|
2017
Q4 | $64K | Buy |
2,294
+230
| +11% | +$7.14K | ﹤0.01% | 2625 |
|
|
2017
Q3 | $75K | Buy |
2,064
+14
| +0.7% | +$433 | ﹤0.01% | 2670 |
|
|
2017
Q2 | $46K | Hold |
2,050
| – | – | ﹤0.01% | 2741 |
|
|
2017
Q1 | $12K | Buy |
2,050
+205
| +11% | +$1.48K | ﹤0.01% | 2810 |
|
|
2016
Q4 | $10K | Hold |
1,845
| – | – | ﹤0.01% | 2882 |
|
|
2016
Q3 | $16K | Sell |
1,845
-14
| -0.8% | -$132 | ﹤0.01% | 2842 |
|
|
2016
Q2 | $18K | Hold |
1,859
| – | – | ﹤0.01% | 2817 |
|
|
2016
Q1 | $17K | Buy |
1,859
+535
| +40% | +$5.3K | ﹤0.01% | 2836 |
|
|
2015
Q4 | $17K | Hold |
1,324
| – | – | ﹤0.01% | 2929 |
|
|
2015
Q3 | $16K | Buy |
1,324
+165
| +14% | +$2.38K | ﹤0.01% | 2910 |
|
|
2015
Q2 | $20K | Hold |
1,159
| – | – | ﹤0.01% | 2997 |
|
|
2015
Q1 | $17K | Buy |
1,159
+145
| +14% | +$1.58K | ﹤0.01% | 3003 |
|
|
2014
Q4 | $9K | Buy |
+1,014
| New | +$9.27K | ﹤0.01% | 2992 |
|
|
2014
Q3 | – | Sell |
-2,298
| Closed | -$42K | – | 3180 |
|
|
2014
Q2 | $42K | Sell |
2,298
-991
| -30% | -$12.9K | ﹤0.01% | 3100 |
|
|
2014
Q1 | $49K | Buy |
3,289
+2,168
| +193% | +$38.9K | ﹤0.01% | 3136 |
|
|
2013
Q4 | $21K | Buy |
+1,121
| New | +$22.4K | ﹤0.01% | 3131 |
|
Guggenheim Capital's AVEO Position: Q1 2023 in Review
Guggenheim Capital sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 13,849 shares — an estimated $207K sold.
Guggenheim Capital first reported a position in AVEO in Q4 2013 and held it in 18 quarters. The position peaked at $207K in Q4 2022. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.
- Guggenheim Capital reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Guggenheim Capital sold 13,849 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $207K.
- Guggenheim Capital first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2013 and held it in 18 quarters.
- Guggenheim Capital's AVEO Pharmaceuticals, Inc. position peaked at $207K in Q4 2022.
- 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.
Based on Guggenheim Capital's 13F filing for Q1 2023, filed 11 May 2023.